Inactive Instrument

Oxis International Stock Euronext Paris

Equities

US6918295014

Pharmaceuticals

Sales 2022 - Sales 2023 - Capitalization 10.56M 9.66M
Net income 2022 -20M -18.3M Net income 2023 -7M -6.4M EV / Sales 2022 -
Net cash position 2022 16.33M 14.94M Net cash position 2023 13.91M 12.73M EV / Sales 2023 -
P/E ratio 2022
-1.35 x
P/E ratio 2023
-1.36 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 89.34%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 61 21-01-12
Corporate Officer/Principal - 22-12-13
Members of the board TitleAgeSince
Director/Board Member 78 23-04-30
Director/Board Member 70 20-11-10
Director/Board Member 79 21-01-12
More insiders
GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system. The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
More about the company